Upgrades, Downgrades, Initiations, May 29
Top Upgrades
- Analysts at Goldman Sachs upgraded Radius Health Inc RDUS from Neutral to Buy. Radius Health shares rose 2.7 percent to $21.80 in pre-market trading.
Top Downgrades
- Goldman Sachs downgraded Clovis Oncology Inc CLVS from Neutral to Sell. Clovis Oncology shares fell 4.2 percent to $15.41 in pre-market trading.
- Goldman Sachs downgraded Esperion Therapeutics Inc ESPR from Neutral to Sell. Esperion Therapeutics fell 4.6 percent to $49.52 in pre-market trading.
Top Initiations
- Baird initiated coverage on Anchiano Therapeutics Ltd ANCN with an Outperform rating. The price target for Anchiano Therapeutics is set to $12. Anchiano Therapeutics shares closed at $4.90 on Tuesday.
- Analysts at Roth Capital initiated coverage on Forty Seven Inc FTSV with a Buy rating. The price target for Forty Seven is set to $28. Forty Seven shares closed at $12.49 on Tuesday.
- Analysts at Berenberg initiated coverage on National Vision Holdings Inc EYE with a Buy rating. The price target for National Vision is set to $38. National Vision shares closed at $27.36 on Tuesday.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.